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Osteogenesis Imperfecta
The Position of Substitution for Glycine by Cysteine in the Triple Helical Domain
of the Proal(I) Chains of Type I Collagen Determines the Clinical Phenotype
Barbra J. Starman,* David Eyre,$' Harry Charbonneau,l Maria Harrylock,l Mary Ann Weis,*
Lester Weiss,11 John M. Graham, Jr.,' and Peter H. Byers* **#
Departments of *Pathology, tOrthopedics, §Biochemistry, and **Medicine, and **the Center for Inherited Disease,
University of Washington, Seattle, Washington 98195; I1Henry Ford Hospital, Detroit, Michigan 48202; and
'Child Development Center, Dartmouth University, Hanover, New Hampshire 03755

Abstract
Skin fibroblasts grown from three individuals with osteogenesis imperfecta (OI) each synthesized a population of normal
type I collagen molecules and additional molecules that had
one or two al(I) chains that. contained a cysteine residue within
the triple-helical domain, a region from which cysteine normally is excluded. The patients had very different phenotypes.
One patient with OI type I had a population of al(I) chains in
which glycine at position 94 of the triple helix was substituted
by cysteine; a patient with 01 type III had a population of al(I)
chains in which glycine at position 526 of the triple helix was
substituted by cysteine; and the third patient, with OI type II,
had a cysteine for glycine substitution at position 718 of the
al(I) chain. From all three patients, molecules that contained
two mutant chains formed interchain, intramolecular disulfide
bonds, and although less stable to thermal denaturation than
normal molecules, they were more stable than molecules that
contained only a single mutant chain. These findings indicate
that substitutions for glycine within the triple-helical domain
of the al(I) chain are not invariably lethal and that their phenotypic effect largely depends on the nature of the substituting
residue and its location in the chain.

Introduction

Osteogenesis imperfecta (01)1 is a remarkably heterogeneous
disorder with phenotypes that range from lethal in the perinatal period to mild, virtually asymptomatic conditions (1, 2). A
variety of molecular defects have been found to cause OI,
including gene rearrangements (3-6), point mutations (7-10),
genomic deletions or splicing mutations that result in deletion
of single exon sequences from the mature mRNA and thus the
protein (1 1, 12), mutations that alter the reading frame in the
gene for either chain of type I procollagen (I 3),2 and mutations
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that alter the amount of type I procollagen synthesized

(14-16).
The relationship between the nature of the mutation and
the clinical phenotype is only beginning to be explored. It
appears that large rearrangements are likely to be lethal if they
are expressed, and that the effect of small deletions may be
determined by their chain location and the domain in the
chain affected. We now present evidence that suggests that
substitutions for glycine in the triple-helical domain of
proal(I) are not always lethal and that the phenotypic effects
of such substitutions depend primarily on the nature of the
substituting residue and its location in the chain.

Methods
Clinical summary
Family 1. The proband was a 2 1-yr-old woman of normal height who
was active in a variety of sports and had had several previous fractures.
On examination she was noted to have light blue sclerae but no dentinogenesis imperfecta or bone deformity. Her mother and all three
siblings also had light blue sclerae and had had occasional fractures.
None had bone deformity, hearing loss, short stature, or dentinogenesis imperfecta. Dermal fibroblasts were grown from the proband and
her mother with appropriate consent.
Family 2. The proband was the second child of healthy nonconsanguinous parents from a town of 10,000 inhabitants in Iraq. The
pregnancy was uncomplicated; the child weighed 2.67 kg and was 16.5
in. long at birth. Apgar scores were 8 and 9. The x rays at birth were
remarkable for wormian bones in the skull, gracile bones of the upper
extremities, short, broad, and bowed femurs, and thin bowed tibias
(Fig. 1). At 6 wk the child was bright and alert. There was a triangular
appearance to the face and the sclerae were blue. There had been at
least one long bone fracture since birth. Both the prior pregnancy and a
subsequent pregnancy resulted in normal infants. At 3 yr of age her
height was 281/4 in. and her weight was 7 kg, both below the third
percentile. She had blue sclerae, opalescent dentin, and small, broken
teeth. Her speech was normal and she was at least average in intelligence. She crawled up stairs and on and off furniture but did not stand
without support. She had bilateral tibial, femoral, and humeral bowing. X rays confirmed the multiple bowing and demonstrated generalized-osteopenia. Dermal fibroblasts were grown from skin biopsies of
both parents and of the affected infant when the child was 6 wk old; all
biopsies were taken with appropriate consent.
Family 3. The proband was the second child of a nonconsanguinous couple whose first child was normal. Ultrasound performed
early in the third trimester identified a fetus with extremely short and
bowed limbs and minimal calvarial mineralization. Elective delivery at
34 wk was performed and the infant died upon delivery. The radiologic
picture was diagnostic of 01 type II, the perinatal lethal form of OI.

Preparation ofprocollagen and collagen
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Dermal biopsies were explanted and fibroblasts grown under standard
conditions in DME (Grand Island Biologicals, Grand Island, NY) as
previously described (17). To label collagenous proteins, dermal fibroblasts were incubated with 2,3,4,5-[3H]proline (100 Ci/mM) or [35S1-
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Figure 1. Radiograph of the proband in family 2.
There are multiple wormian bones in the skull, the
ribs are thin without evidence of previous fracture,
the femurs are short and bowed, and the tibias are
bowed.

cysteine (1,010 Ci/mM; both from Amersham Corp., Arlington
Heights, IL) under conditions previously described (17, 18). Medium
and cell-layer proteins were harvested separately in the presence of
protease inhibitors (17, 18) and concentrated by ethanol precipitation
(30% vol/vol) after addition of carrier collagen (25 ,Ag/ml; Sigma
Chemical Co., St. Louis, MO). Digestion of procollagen with pepsin
(50 jug/ml; Boehringer Mannheim Biochemicals, Inc., Indianapolis,
IN) was carried out for 2 h at 1 8°C in 0.5 M acetic acid adjusted to pH
2.0 with HCI. The reaction was stopped by the addition of pepstatin
and lyophylization.

Characterization of collagen by SDS-PAGE
Proa chains were separated under reducing conditions in 5% acrylamide slab gels containing SDS and 2 M urea (17, 19); collagens were
separated in the same gels under nonreducing conditions. In some
experiments proteins separated in one dimension were cleaved in the
gel with cyanogen bromide and the resultant peptides were analyzed by
electrophoresis in a second dimension gel (18).

Determination of thermal stability
Thermal stability of pepsin-digested procollagens was determined as
previously described ( 17, 18, 20).

Preparation of sample for determination of
partial amino acid sequence
To prepare collagen chains for microsequence analysis, 10 100-mm
dishes (Corning Glass Works, Corning, NY) were grown to confluence
and proteins were labeled with [3H]proline the first day and with [35S]cysteine the next day using conditions outlined above except that no
carrier collagen was added to the harvested medium. The medium was
collected, dialyzed into 30 mM Tris-HCl, 20 mM NaCl, 2 M urea, pH
7.6, at 4°C, applied to a DEAE-cellulose column (DE-52, 12 X 150
mm; Whatman Laboratory Products Inc., Clifton, NJ) in the same
buffer, and eluted with a 300-ml linear gradient from 0 to 100 mM
NaCl (21). Type I procollagen was dialyzed into 10 mM NH4HCO3
and lyophylized.
The methods for isolating the fragment of the triple-helical domain
of the a 1(I) chain that contained the cysteine residue differed slightly
with each mutation.
In the first family the type I procollagen was cleaved with pepsin,
the cysteine residues in the a chains were modified with 4-vinyl pyridine (22), and the chains were separated by reverse-phase HPLC (23,
24). The a 1(I) chains were collected, dried, and then cleaved with
trypsin and the 35S-containing al(I)CB5 peptide was recovered by a
second HPLC step. This peptide was digested with trypsin (sequencing
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grade; Boehringer Mannheim Biochemicals, Inc.) in 0.1 M NH4HCO3
and the resulting 35S-containing fragment was again isolated by reverse-phase HPLC. The peptide was then dried and subjected to
Edman degradation using a gas-phase automated microsequencer
(model 470A; Applied Biosystems Inc., Foster City, CA). A portion of
the output at each cycle was analyzed on line for PTH-amino acids
(model 120A online PTH analyzer; Applied Biosystems Inc.) and the
remainder was collected to determine the content of radioactivity by
scintillation counting.
In the second family the cysteines in the isolated proa chains of
type I procollagen were reduced and carboxymethylated with iodoacetate after reduction for 4 h in 8 M urea with DTT. Sodium iodoacetate
was added to a final concentration of 20 mM and after 15 min a fresh
aliquot of DTT was added and the sample was dialyzed into 0.1 M
acetic acid before lyophylization. The dried sample was digested with
cyanogen bromide for 24 h and the resulting peptides were separated
by reverse-phase HPLC (see below for details). The tubes that contained aI(I)CB3 were pooled and dried. Purified al(I)CB3 was cleaved
at the single Asn-Gly bond in the peptide with hydroxylamine (25).
The sample was dissolved in water and warmed to 40°C, an equal
volume of cold 2 M NH2OH, pH 10.5, was added, and the mixture was
incubated at 35°C for 90 min. The sample was then frozen before
separation of the fragments. The new peptides were resolved by HPLC
(see below) and the 35S-containing fragment was identified by liquid
scintillation counting. The labeled fragment was dried and subjected to
automated peptide sequence analysis. For the first eight cleavages 80%
of the sample was committed to identification of PTH-amino acids
and the remainder was monitored by liquid scintillation counting; the
entire sample was counted for products of cleavages 9-29.
After purification of type I procollagen synthesized by the cells
from the patient in family 3, the molecules were cleaved with pepsin
and the cysteine residues in the a chains were reduced with DTT and
alkylated with 4-vinyl pyridine. The chains were cleaved with cyanogen bromide and a I (I)CB7 was separated by reverse-phase HPLC. The
peptide was then cleaved with trypsin and the fragment that contained
35S was isolated by reverse-phase HPLC and then subjected to sequence determination as above.

Separation ofpeptides by HPLC
Whole a chains and peptides obtained from type I procollagen after
cleavage with cyanogen bromide and cleavage of aI(I)CB3 with hy-
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Results
Cysteine in the aJ(I) chain of type I collagen. Dermal fibroblasts cultured from two of the three probands (probands from
families 2 and 3) synthesized normal type I procollagen and
type I procollagen whose chains had delayed electrophoretic
mobility when examined by SDS-PAGE under reducing conditions (Fig. 2 A). The delay in mobility was abolished by
incubation of cells in a,a'-dipyridyl to block prolyl and lysyl
hydroxylation (not shown). In the third proband, the individual from family 1, we did not identify any alteration in mobility or in the efficiency of secretion of type I procolla;en. When
the amino- and carboxyl-terminal propeptides of type I procollagen were removed by cleavage with pepsin and the products were examined by SDS-PAGE in the absence of reduction
of disulfide bonds, there was in each cell strain a band that
migrated between the a 1(I) chains and the trimer of a 1(III)
that was not synthesized by control cells or by cells from unaffected family members. The electrophoretic mobilities of the
new band differed slightly with each cell strain. In all three
cases the new chain migrated with chains in the region of a 1(I)
under reducing conditions (not shown). In addition, in the
Famjiy
Medium '"e ITs

proal(III)

proc32(l)-IIj

droxylamine were dissolved in 1% trifluoracetic acid and separated by
reverse-phase chromatography on C4, C8, or C18 macroporous columns. The starting solvent, A, consisted of 5% (vol/vol) acetonitrile in
0.1% (vol/vol) trifluoroacetic acid. Solvent B consisted of 3:1 (vol/vol)
acetonitrile/n-propanol in 0.1% trifluoroacetic acid. Whole a 1(I)
chains were separated on a Brownlee Aquapore RP-300 column (C8;
25 cm X 4.6 mm; Applied Biosystems Inc.) or a 214TP54 column (C4;
25 cm X 4.6 mm; Vydac, Hesperia, CA) by a gradient of 15-30% B in
50 min. Cyanogen bromide peptides were separated by a linear gradient of 5-15% B in 40 min (al[I]CB5, family 1), or a complex gradient of 8-30% B in 60 min (al[I]CB3, family 2; al[I]CB7, family 3)
on the Brownlee RP-300 column. Hydroxylamine peptides were separated by a linear 0-25% B gradient over a period of 40 min. Tryptic
peptides were resolved on the same column using a linear gradient of
0-30% B in 60 min. All column effluents (1 ml/min) were monitored
for absorbance at 220 nm, and for 3H and 35S radioactivity by liquid
scintillation counting.
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Figure 2. Proa and a chains synthesized by
cells from family 1 (A), family 2 (B), and
the proband in family 3 (C). In each group
proa chains separated under reducing conditions are in the top panel and collagen
chains separated under nonreducing conditions are in the bottom panel. In the bottom panel of each a new band is visible
that migrates between a I(I) and (al [II1)3;
the mobility of the band differs in each patient. In A (top panel) the two OI panels
are from the affected mother and one
daughter (the proband); the control (C) is a
nonfamily control. In the bottom panel
only the proteins synthesized by the daughter's cells are shown. In B and C, OI, affected; F, unaffected father; M, unaffected
mother; C, control.

samples from families 2 and 3 there was a band that migrated
just slower than the normal al(I) (Fig. 2 B). The amount of the
abnormal band that remained within the cells differed among
the three cell strains; there was virtually none in the cells from
the proband in family 1 and increasing amounts in the probands from families 2 and 3, respectively.
Localization ofthe new cysteine residues in aJ (I). To characterize the abnormal bands synthesized by cells from the probands, we separated the pepsin-treated [3H]proline-labeled collagenous proteins in the first dimension under nonreducing
conditions, cleaved the proteins in the gel with cyanogen bromide, and examined the peptides in a second dimension gel
under nonreducing and reducing conditions. When the peptides were separated under reducing conditions, in each case
the band that migrated between al(I) chains and the (al [III)3
molecules gave rise to the peptides of al(I) (Fig. 3). Under
nonreducing conditions the expected peptides from the new
chain synthesized by cells from the proband in family 1 were
all present but the partial fragment al(I)CB5-8 was missing
(residues 86-401; Fig. 3 A), which suggested that the cysteine
was in the domain of a l(I)CB5.
When the peptides from the al(I) dimer synthesized by the
cells grown from the proband in family 2 were separated under
nonreducing conditions all the peptides except al(I)CB3 were
present and an additional band of about the size of a dimer of
a l(I)CB3 was evident (Fig. 3 B, left panel). When the peptides
were separated under reducing conditions in the second dimension, all the peptides of al(I), including al(I)CB3, wereseen (Fig. 3 B, right panel). This indicated that the abnormal
molecules synthesized by the proband contained a cysteine
residue in the domain of al(I)CB3 (triple-helical residues
402-551), a region from which cysteine is normally excluded.

A Family
*

o01(i)

c42(l)
xl(1)CB5-8
c,l(1)CB7 -

B Family 2
A

Uv

5.

9.F
S

I1(I)

2 4 5

C Family 3

*B

cd2()

4
cxI(I)CB8 F
cx(l)CB6 cx(l)CB3 -

The electrophoretic mobility of a l(I)CB7, a l(I)CB8, and
al(I)CB6 from the dimer were normal; that of al(I)CB3 was
delayed. In contrast, the electrophoretic mobilities of
al(I)CB8 and al(I)CB3 derived from the band that migrated
slightly slower than al(I) were delayed, while those of
al(I)CB7 and al(I)CB6 were normal. These findings suggested
that in this cell strain overmodification extended over a longer
domain in molecules that contained a single mutant chain
than in molecules that contained two mutant chains joined by
a disulfide bond.
To better localize the new cysteine residue in proband 2,
we separated [35S]cysteine-labeled a chains in the first dimension by SDS-PAGE, cleaved them in the gel with hydroxylamine, and separated the resulting peptides in the second dimension. The major cysteine-containing band migrated more
slowly than a l(I)CB7 (271 residues) and more rapidly than the
partial cleavage fragment al(I)CB7-6 (463 residues; not
shown). This placed the new cysteine residue in both the
al(I)CB3 fragment (residues 402-551) and the large hydroxylamine fragment (residues 523-980) and located it between
residues 523 and 551.
When the peptides from the al(I) dimer synthesized by
cells from the proband in family 3 were examined under
nonreducing conditions all the peptides except for al(I)CB7
were identified (Fig. 3 C). The peptides from the slowly migrating a 1(I) chain all migrated more slowly than those from
the normal chain except for a l(I)CB6, the carboxyl-terminal
peptide of the triple-helical domain. These results indicated
that overmodification of the chains in abnormal molecules
began in a 1(I)CB7 and extended to the amino-terminal end of
the molecule and that the new cysteine was situated between
residues 552 and 822.
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Figure 3. Cyanogen bromide peptides from the normal and abnormal chains and the a 1(I) dimer synthesized by cells from the probands in
families I (A), 2 (B), and 3 (C). [3H]Proline-labeled procollagen secreted by cells from the proband were digested with pepsin and the a chains
were separated in the first dimension under nonreducing conditions and cleaved in the gel with cyanogen bromide; the peptides were then separated in the second dimension under nonreducing conditions. For the right panel in B the peptides were separated under reducing conditions in
the second dimension. The position of the new band in the first dimension gel is marked with an asterisk. A, Peptides from the dimer separated
under nonreducing conditions show no evidence of the partial cleavage fragment al(I)CB5-8. This locates the cysteine in al(I)CB5. B, Under
nonreducing conditions (left panel) a 1 (I)CB3 from the dimer (*) is not seen but a new band is present above a l(I)CB5-8 (arrow). Under reducing conditions al(I)CB3 is present (arrow), although the electrophoretic mobility is slower than that of the normal a l(I)CB3. These findings indicate that the new cysteine is in al(I)CB3. C, Under nonreducing conditions there is a new fragment from the a 1(I) dimer that migrates near
the position of a2(I)CB3-5 and all the peptides with the exception of al(I)CB6 are overmodified. This indicates that the cysteine is located
amino-terminal to al(I)CB6 in the domain of al(I)CB7. A diagrammatic representation of the cyanogen bromide peptides of the triple-helical
domain of the al(I) chain is located below.
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Identification of substituted residues. We then labeled procollagens with [3H]proline and [35S]cysteine, purified type I
procollagen by DEAE-cellulose chromatography, isolated by
HPLC the cysteine-containing fragments created by chemical
and/or enzymatic cleavage, and determined the radioactive
and, when possible, the chemical sequence ofthe fragments. In
this manner we determined that in family 1 the cysteine replaced glycine at position 94 of the triple helix of the a 1(I)
chain, in proband 2 the cysteine replaced glycine at position
526 of the triple helix of the a 1(I) chain, and in proband 3 the
cysteine replaced glycine at position 718 of the triple helix of
the I(I) chain (Fig. 4). In the collagens synthesized by the
probands in families 1 and 3 the site of the cysteine for glycine
substitutions was revealed by coincident 35S radioactivity and
the PTH derivative of pyridinylethyl cysteine together with a
a
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sequences below each
panel are of the normal
a 1 (I) chains; position 1
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triple-helical domain. A,
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Figure 4. Profile of radiolabeled amino acids
after automated Edman
degradation sequence
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efficiency. Each residue
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PTH derivative, except
that the glycine at position 94 in the normal

identified
modified cysteine.
B, The counts in the
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92% cleavage efficiency
E
200
at each cycle. For the
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first eight turns the
PTH-derived amino
acids were isolated and,
although the levels were
A I D
low, alanine in the sec0
Major VGPPGPSGNAGPPGPPGPAGK
ond position, aspartic
acid in the sixth position, and alanine in the
eighth position could be identified. The placement of the radiolabeled proline residues and the directly identified residues confirmed
the identity of the fragment and the isolation of [35S]cysteine at the
fourth cycle and indicated that there had been a cysteine for glycine
substitution at residue 526 of the triple-helical domain of the a (I)
chain. C, Two tryptic peptides were identified for their full length
during sequence analysis. The major sequence contained the residues
in the triple helix of a 1(I) from 704 to 725 and the minor sequence
was derived from 421 to 434 of the triple helix of a (I). All residues,
including the modified cysteine at 718, were identified. Each residue
in all three panels is identified by the single letter code: A, alanine; D,
aspartic acid; E, glutamic acid; G, glycine; K, lysine; L, leucine; M,
methionine; N, asparginine; P, proline; Q, glutamine; R, arginine; S,
serine; V, valine; P*, hydroxyproline.
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sequence was
as a

C Family 3

major running sequence for the tryptic peptide. In the peptide
around the mutant site in families 2 and 3 the proline that preceeded the cysteine appeared to be fully hydroxylated considering the PTH amino acid yield.
Abnormal molecules have a low thermal stability. In all
three cell strains in which there is a cysteine for glycine substitution, the type I procollagen molecules that contained two
abnormal chains (as evidenced by the presence of interchain
disulfide bonds) melted at lower temperatures than control
molecules, but at higher temperatures than those molecules
that contained only a single abnormal chain (Fig. 5). In collagens synthesized by cells from proband 1, molecules that contained the disulfide bonded I(I) dimer melted between 41
and 42°C, and the abnormal molecules that contained a single
abnormal chain melted between 39 and 40°C; in those from
proband 2, the dimer melted between 40 and 41 °C, and the
molecules that contained a single abnormal chain melted at
39.5°C; in those from proband 3, the dimer melted between
37 and 38°C and the molecules that contained a single abnormal chain melted at 37°C. In each instance the single mutant chain (cysteine labeled) in the abnormal molecules was
susceptible to proteolysis at a lower temperature than the normal chain (proline labeled) that had become overmodified.
sequences

a

-

-

Discussion
We have identified three separate families in which the presence of a cysteine residue within the triple-helical domain of
the proa 1 (I) chain of type I procollagen results in an 01 phenotype. The clinical result of the mutations is strikingly different:
glycine to cysteine at residue 94 ofthe triple helix results in the
mild 01 type I phenotype; glycine to cysteine at residue 526
results in the moderate 01 type III phenotype; and glycine to
cysteine at residue 718 results in the perinatal lethal 01 type II
phenotype.
The marked clinical heterogeneity in 01 has been difficult,
to explain clearly on the basis of biochemical findings. The
mildest dominantly inherited form, OI type I, often results
from mutations that alter the amount of normal type I procollagen secreted by cultured cells (14-16). Rarely, it may result
from deletion of all of a COLlAl allele (Willing, M. C., and
P. H. Byers, unpublished observations), but more commonly
appears to result from a variety of other mutations that affect
the synthesis of proal(I) chains (14-16), the incorporation of
proa 1 (I) chains into type I procollagen,2 the rapid intracellular
degradation of abnormal type I procollagen molecules, or evidence of an altered sequence within the telopeptide domain of
the 1 (I) chain (26); linkage of the phenotype to mutations in
both COLlA 1 and COL1A2 is consistent with these biochemical and molecular genetic findings (27, 28).
In most instances the perinatal lethal form, 01 type II,
results from substitutions for single glycyl residues within the
triple helical domain of a 1 (I) or a2(I). These mutations appear
to interfere with the formation of stable triple helix, delay
secretion of molecules that contain mutant chains, alter the
extent of posttranslational modification of all chains in molecules that carry a defective chain (17), interfere with aminoterminal propeptide cleavage, and result in an abnormal
structure of type I procollagen molecules that may affect fibrillogenesis (29). In rare instances the 01 type II phenotype
may result from mutations that result in deletion or insertion
of coding material (3-6).
a
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FigureS. Thermal stability of
the collagen molecules synthesized by cells from the probands in families 1 (A), 2 (B),
and 3 (C). Proteins analyzed
in each top panel were biosynthetically labeled with [3H]proline and those in the bottom were labeled with [35S]cysteine. In B, lane 1 of the
top panel contains [35S]cysteine-labeled proteins and
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Between these extremes lies a large group of individuals
with 01, classified on clinical grounds as either 01 type III
(progressive deforming) or OI type IV (dominantly inherited
with non-blue sclerae and often accompanied by dentinogenesis imperfecta) and ranging in severity from mild to moderately severe (1, 2). Relatively few mutations that produce these
disorders have been identified. A 4-bp deletion near the 3' end
of the coding region of the proa2(I) chain that altered the last
12 residues of the chain and prevented its assembly into type I
procollagen molecules produced an OI type III phenotype in
the homozygous state but had little phenotypic effect in the
heterozygotes (13, 30). Deletion of single exons encoding domains near the amino-terminal end of the triple helix of the
proa2(I) chain (11) or near the center of the triple helix (31)
have produced mild-to-moderate phenotypes, as has a substitution of arginine for glycine near the carboxyl-terminal end of
the triple-helical domain of proa2(I) (32). This list, however,
emphasizes the difficulty in providing a cohesive understanding of the genotype-phenotype relationship in the mild-tomoderate 01 phenotypes.
We think that our findings in the three families studied
here, in addition to the accumulation of mutations rapidly
being identified, begin to help understand some aspects of the
relationships between mutation and phenotype. It is striking
that there is progressive improvement of phenotype as the
same point mutation, substitution of cysteine for glycine,
Biochemical-Clinical Correlation in Osteogenesis Imperfecta
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Table I. Sequences around Known Cysteinefor Glycine Substitutions in the Proal (I) Chains of Type I Procollagen
94

AlaGlyLeuHypGlyMetLysGlyHisArgGlyPheSerCysLeuAspGlyAlaLysGlyAspAlaGlyProAlaGlyProLysGlyGluHyp
175

AlaGlyProHypGlyPheHypGlyAlaValGlyAlaLysCysGluAlaGlyProGlnGlyProArgGlySerGluGlyProGlnGlyValArg
526

HypGlyProAlaGlyProArgGlyAlaAsnGlyAlaHypCysAsnAspGlyAlaLysGlyAspAlaGlyAlaHypGlyAlaHypGlySerGln
718

ValGlyProHypGlyProSerGlyAsnAlaGlyProHypCysProHypGlyProAlaGlyLysGluGlyGlyLysGlyProArgGlyGluThr
748

ThrGlyProAlaGlyArgHypGlyGluValGlyProHypCysProHypGlyProAlaGlyGluLysGlySerHypGlyAlaAspGlyProAla
904

ThrGlyProAlaGlyProAlaGlyProValGlyProAlaCysAlaArgGlyProAlaGlyProGlnGlyProArgGlyAspLysGlyGluThr
988

AspGlyLeuAsnGlyLeuHypGlyProIleGlyProHypCysProArgGlyArgThrGlyAspAlaGlyProValGlyProHypGlyProHyp
The mutant sequences are compiled from the following sources: cysteine for glycine at residues 94, 526, and 718 (this report); 175;3 748 (8);
904 (34); 988 (7). The substitution at 94 procedures the OI type I phenotype; the substitution at 175 produces clinical variability (33) but
largely OI type IV; the substitution at 526 produces 01 type III; the substitutions at 718, 748, 904, and 988 all produce the 01 type II lethal
phenotype.

moves toward the amino-terminal end ofthe triple helix of the
proal(I) chain. This movement is accompanied by increased
efficiency of secretion of molecules that contain abnormal
chains, increased thermal stability of those molecules, and decreased extent along the molecule in which overmodification
occurs. Because cysteine is normally excluded from the triplehelical domain of proa l(I), substitutions in the chain can be
identified by the formation of an a 1(I) chain dimer. Lethal
point mutations have been identified that result in substitutions of cysteine for glycine at positions 988 (7), 904 (33), and
748 (8) in the triple-helical domain, and a milder form results
from substitution for glycine at position 175 (34).3 These families fit the generalization that mutations that result in substitution of cysteine for glycine are more severe in their phenotypic consequences when they occur near the carboxyl-terminal
end of the triple-helical domain of proa I(I) than at the
amino-terminal end.
This end-rule or phenotypic gradient for mutations along
the proal(I) chain probably depends on the nature of the substituting amino acid. We are aware, for example, that substitution of arginine for glycine at positions 391 (9) or 664 (10)
results in a lethal 01 phenotype and that substitution for glycine by arginine at position 154 results in the 01 type III phenotype.4
Inspection of the sequence motifs around the lethal and
nonlethal cysteine for glycine substitutions (Table I) does not
clearly identify specific domains which, when altered, produce
lethal phenotypes. For example, the substitutions at 718 and
748 both disrupt the hexapeptide GlyProHypGlyProHyp and
are lethal. The substitution at 988 substitutes a glycine that
succeeds a potentially hydroxylatable prolyl residue and the
substitution is in a region bounded by additional hydroxyproline residues. In contrast, the substitution at 904 is in a region
entirely devoid of hydroxyproline and would ordinarily be
3. Hollister, D., personal communication.
4. Pruchno, C. J., B. J. Starman, and P. H. Byers, unpublished observations.
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considered a relatively loose triple-helical domain. The nonlethal substitutions at 94 and 175 are in regions that are not
rich in hydroxyproline and would probably be considered intermediate in stability. The substitution at 526 succeeds a hydroxylatable prolyl residue and is embedded in a region of
moderate hydroxyproline content; if hydroxyproline content
alone determined the phenotype, then this would be considered a candidate for a lethal mutation. Given these considerations, it appears that the nature of the substitution and its
location in the chain are the major determinants of the phenotypic outcome of a point mutation. Because cysteine residues in the triple-helical domains of fibrillar collagens, in contrast to other substitutions, have the potential for covalent
interactions with other molecules within the cell and in the
matrix, cysteine substitutions may differ in their effects from
those of other residues.
The prolyl residues that preceded the new cysteines in the
abnormal a 1(I) chains synthesized by cells from the probands
in family 1 (position 93) and family 3 (position 717) were
hydroxylated. These observations suggest that prolyl 4-hydroxylase may recognize general context as well as specific sequence.
The stability to thermal denaturation of the chains in molecules that contained one mutant and one normal a 1(I) chain
were not equivalent and the first proteolytic cleavage appeared
in the abnormal chain. The sequences around the mutation
sites in each chain we characterized include basic residues that
would be cleaved by the trypsin in the incubation mixture
(Table I). Our observations suggest that the conformation of
the single mutant chain is altered more than that of the two
normal chains and, further, that the disulfide bond created in
molecules with two abnormal chains acts to stabilize those
chains in a less available conformation.
Finally, the findings in family 2 have an additional important implication in that they confirm that the OI type III phenotype can result from dominant mutations that result in substitutions for glycine residues in the triple helix of the a 1(I)
chain of type I collagen. Until now, clinical genetic (2, 35) and
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biochemical studies (13) have been interpreted to indicate that
this form of OI is usually inherited in an autosomal recessive
fashion. The findings in this family, additional sequence determination,4 and our survey of individuals with moderately severe OI phenotypes (Wenstrup, R. J., M. C. Willing, B. J.
Starman, and P. H. Byers, manuscript submitted for publication) all suggest that a significant proportion of individuals
with the O1 type III clinical phenotype result from dominant
mutations which, in some families, are inherited.
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